gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Myeloproliferative leukemia virus oncogene

MPL, c-Mpl, thrombopoietin receptor
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: thrombopoietin, JAK2, CAN, HAD, MPN
Papers on MPL
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation.
Fukuda et al., Tokyo, Japan. In Biol Blood Marrow Transplant, Feb 2016
Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized.
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi, Rochester, United States. In Am J Hematol, Jan 2016
In 2005, William Vainchenker and others described a Janus kinase 2 mutation (JAK2V617F) in MPN and this was followed by a series of additional descriptions of mutations that directly or indirectly activate JAK-STAT: JAK2 exon 12, myeloproliferative leukemia virus oncogene (MPL) and calreticulin (CALR) mutations.
Highly variable mutational profile of ASXL1 in myelofibrosis.
Zamora et al., Badalona, Spain. In Eur J Haematol, Jan 2016
METHODS: We analysed mutations in ASXL1 in 70 consecutive MF patients from 8 spanish hospitals by means of Sanger sequencing, as well as JAK2, CALR and MPL mutations.
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation.
Musto et al., Italy. In Oncotarget, Jan 2016
miR-27b/MPL, miR-21/ANXA1, miR-181/EGR2), indicating that EV content was able to modify gene expression profile of receiving cells.
Monoclonal antibody 1.6.1. against human MPL receptor allows HSCs enrichment of CB and BM CD34(+)CD38(-) population.
Souyri et al., Villejuif, France. In Exp Hematol, Jan 2016
UNASSIGNED: Thrombopoietin (TPO) and its receptor Mpl (CD110) play a crucial role in the regulation of hematopoietic stem cells (HSCs).
HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.
Rosa et al., São Paulo, Brazil. In Plos One, Dec 2015
Furthermore, we demonstrate that combining some adjuvants like MPL plus Alum and MPL plus MDP exert additive effects that impact on the magnitude and quality of humoral responses while mixing MDP with poly (I:C) or with R848 had no impact on total IgG titers but highly impact IgG subclass.
Current Management of Primary Immune Thrombocytopenia.
Newland et al., London, United Kingdom. In Adv Ther, Nov 2015
A new class of drugs, the thrombopoietin receptor agonists, has been developed for use in ITP.
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Bailey et al., Manchester, United Kingdom. In Lancet, Nov 2015
BACKGROUND: The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia.
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.
Plo et al., Villejuif, France. In Nat Genet, Oct 2015
ATG2B and GSKIP cooperate with acquired JAK2, MPL and CALR mutations during MPN development.
[Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
Wei et al., Taiyuan, China. In Zhongguo Shi Yan Xue Ye Xue Za Zhi, Oct 2015
In 2008, WHO made the JAK2V617F gene mutation as one of the specific molecular diagnostic markers of BCR/ABL-negative myeloproliferative neoplasms (MPN).
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
Snyder et al., Bern, Switzerland. In N Engl J Med, Oct 2015
CALR and MPL mutant allele burdens were also reduced by 15 to 66%.
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Levine et al., New York City, United States. In Cancer Cell, Aug 2015
JAK2 and MPL mutant cell lines were sensitive to CHZ868, including type I JAK inhibitor persistent cells.
Use of a novel floxed mouse to characterise the cellular source of plasma coagulation FXIII-A.
Grant et al., Montréal, Canada. In Lancet, Mar 2015
The resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murine model.
Pacritinib: a new agent for the management of myelofibrosis?
Harrison et al., London, United Kingdom. In Expert Opin Pharmacother, 2014
INTRODUCTION: Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F, MPL, CALR) and constitutive activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription pathway.
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.
Gardie et al., Nantes, France. In Mediators Inflamm, 2014
Recent advances in the biology of MPNs have greatly facilitated their molecular diagnosis since most patients present with mutation(s) in the JAK2, MPL, or CALR genes.
The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
Mulloy et al., Cincinnati, United States. In Blood, 2012
High MPL expression is associated with leukemia.
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Castilla et al., Worcester, United States. In Blood, 2012
Up-regulation of wild-type MPL levels promotes leukemia development and maintenance through activation of the PI3K/AKT axis.
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Rumi et al., Pavia, Italy. In Am J Hematol, 2012
genetic association studies in Italian population: Data suggest that JAK2 GGCC haplotype is associated with JAK2 mutation (V617F) but is not associated with MPL mutation in exon 10 in myeloproliferative neoplasm subjects. [meta-analysis included]
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Constantinescu et al., Brussels, Belgium. In Blood, 2012
Selection against TpoR antiproliferative signaling occurs by TpoR down-modulation and that restoration of down-modulated TpoR levels could become a biomarker for the treatment of myeloproliferative neoplasms.
[EPOR and TPOR expressions on CD34+ CD59- and CD34+ CD59+ bone marrow cells from patients with paroxysmal nocturnal hemoglobinuria].
Sha et al., Tianjin, China. In Zhonghua Xue Ye Xue Za Zhi, 2011
The expression of EPOR and TPOR on CD34+ CD59+ bone marrow cells are significantly higher than those on CD34+ CD59- cells of paroxysmal nocturnal hemoglobinuria patients.
share on facebooktweetadd +1mail to friends